Stock Watch: The Biotech Departure Lane From Europe
Exacting European Reimbursement Systems Cannot Be Mastered Without Outcomes Evidence
It is not only gene therapy companies that have found European payers hard to convince of the value of their products. Amarin’s proposed European pricing may lead to another US company exit.
